According to research reviewed by Gram, lowering a protein called GPR146 in the liver reduced artery plaque and inflammation in mice fed a high-fat diet. In the 12-week study, lower GPR146 also cut circulating LDL cholesterol and calmed immune cells linked to plaque buildup. These findings are preclinical and do not yet apply directly to people.
A new study looked at a protein called GPR146 and how it affects clogged arteries. Researchers found that GPR146 was more active in the sticky plaque that builds up inside artery walls. In mice fed a high-fat diet, lowering GPR146 in the liver reduced plaque size, lowered blood cholesterol, and calmed inflammation inside the plaque. Lab experiments with immune cells suggested the protein helps them store fat and stir up inflammation, partly through a signaling pathway called JAK-STAT. According to research reviewed by Gram, these results point to GPR146 as a possible future drug target. However, the work was done in mice and cells, so it does not yet show that the same approach would help people with heart disease.
Key Statistics
A 2026 study published in Biochemical Pharmacology found that lowering the liver protein GPR146 reduced atherosclerotic plaque in mice that had been fed a high-fat diet for 12 weeks.
The same 2026 study found that reducing GPR146 in ox-LDL-stimulated macrophages lowered lipid accumulation and reduced CD36 expression, which decreased foam cell formation in laboratory cell experiments.
A 2026 mouse and cell study reported that reduced GPR146 was accompanied by lower JAK2 and STAT3 expression, pointing to the JAK-STAT signaling pathway as a possible route for its inflammatory effects.
The Quick Take
- What they studied: Scientists wanted to know whether a protein called GPR146 links fat metabolism in the body to inflammation inside artery plaque, the fatty buildup that can narrow blood vessels.
- Who participated: The main experiments used laboratory mice that were bred to develop clogged arteries. The study also used immune cells grown in a lab dish. The exact number of animals and cells was not stated in the summary.
- Key finding: Lowering GPR146 in the liver of mice reduced plaque in their arteries, lowered total and LDL cholesterol in the blood, and reduced inflammation within the plaque. The summary does not give exact percentages, so the size of the effect is not clear.
- What it means for you: This is early research and does not mean you should change your diet or medicines based on it. Heart-healthy habits with proven benefits, such as eating more fiber, staying active, and following your doctor’s advice on cholesterol, remain the best steps today.
The Research Details
Researchers fed mice a high-fat diet for 12 weeks so that their arteries would develop plaque, similar to how fatty buildup forms in people who eat a lot of fat and cholesterol. After that, the team used a harmless virus to lower GPR146 in the mice’s livers for 4 weeks. Another group of mice received rosuvastatin, a common cholesterol-lowering medicine, to compare results.
To look at the plaque itself, the scientists used special stains and microscope techniques. They measured blood fats and inflammation markers using standard lab tests. They also studied the immune cells that take up fat and turn into the foamy cells found in plaque.
In a separate set of experiments, the team turned down GPR146 in immune cells grown in a dish and exposed them to a damaged form of LDL cholesterol. They then looked at which genes changed and tested whether blocking the JAK-STAT signaling pathway could copy the effects.
Using both living mice and lab cells lets scientists see a process from several angles. Mouse studies can show how a change affects the whole body, while cell studies help reveal the specific steps involved. Together, they make a stronger case for a biological link than either method could alone.
The study used standard, well-recognized methods and tested a known medicine as a comparison, which helps readers judge the results. However, mouse and cell studies do not always translate to humans. The summary also does not state how many animals or cell samples were used, which makes it harder to judge how reliable the numbers are.
What the Results Show
In mice, the researchers found that GPR146 was more active in areas of artery plaque that were full of immune cells called macrophages. This suggests the protein may be involved in how plaque grows and becomes inflamed.
When GPR146 was lowered in the liver, the mice had smaller plaques and lower levels of total cholesterol and LDL cholesterol, which is often called the bad kind. They also had less damaged LDL and less inflammation within their plaques. These changes point to a possible link between liver fat handling and the health of artery walls.
In lab experiments, immune cells with less GPR146 took up less damaged LDL cholesterol. They also produced fewer signals that drive inflammation and were less likely to turn into the foamy cells that make up plaque. The cells also showed less of a receptor called CD36, which helps them grab fat.
The team’s gene analysis pointed to the JAK-STAT signaling pathway, a chain of chemical messages inside cells. When GPR146 was reduced, the cells made less JAK2 and STAT3, two parts of that pathway. Blocking the pathway with a drug partly copied the anti-inflammatory effects seen when GPR146 was lowered.
The study suggests that GPR146 affects more than one process at once. It appears to influence how the liver handles cholesterol, how immune cells store fat, and how they respond with inflammation. This matters because plaque growth depends on all three. Looking at several steps together may explain why lowering this one protein had broad effects.
Earlier work had already suggested that GPR146 plays a role in regulating cholesterol, so this study builds on that idea. It goes further by connecting cholesterol control with inflammation inside artery plaque. This fits a growing view that heart disease needs treatments that address both fat buildup and inflammation, not just cholesterol levels.
The most important limitation is that the work was done in mice and in cells grown in a dish. Mice are not people, and results often change when tested in humans. The summary also does not give exact sample sizes, detailed numbers, or how long effects lasted after treatment. Blocking JAK-STAT only partly matched the effects of lowering GPR146, so the full picture is still unclear. More research is needed before anyone can say whether this protein is a safe or useful treatment target.
The Bottom Line
Right now, the evidence is early and comes from animals and lab cells, so no treatment recommendation can be made for people. The findings are a reason for further study, not a reason to change care. Proven steps, such as eating less saturated fat, eating more vegetables and whole grains, exercising regularly, not smoking, and taking cholesterol medicines when a doctor prescribes them, remain well supported. Confidence that GPR146 will become a useful treatment is low to moderate at this stage.
Researchers who study heart disease, cholesterol, and inflammation should pay close attention, since this could guide new drug development. People with heart disease or high cholesterol may find the topic interesting, but should not expect any immediate changes to care. Anyone with questions about their own heart health should talk with a doctor rather than rely on this early research.
Turning an idea like this into a medicine usually takes many years. The next steps would include more animal testing, safety checks, and eventually human clinical trials. Most people should not expect any new treatment based on GPR146 for a long time, and it is not clear that one will ever reach the market.
Frequently Asked Questions
What did the 2026 GPR146 study find about artery plaque?
In mice fed a high-fat diet for 12 weeks, lowering GPR146 in the liver reduced the size of atherosclerotic lesions. The protein was also more active in plaque areas rich in immune cells, suggesting it helps drive plaque growth and inflammation. The research is preliminary and has not been tested in people.
Is GPR146 a cholesterol-lowering target for people?
GPR146 is being studied as a possible future drug target, but it is not yet an established one. In mice, lowering it reduced total and LDL cholesterol, which is promising. Human trials would be needed before any treatment could be recommended for people.
How does inflammation contribute to clogged arteries?
Immune cells called macrophages take in fat and become foamy cells that build up inside artery walls. They also release inflammatory signals that can make plaque grow and become unstable. Research such as the GPR146 study explores ways to calm this process, though current treatments remain the standard approach.
What can I do now to protect my heart from plaque buildup?
Eating more vegetables, whole grains, and fiber while limiting saturated fat supports healthy cholesterol. Regular physical activity, not smoking, and managing blood pressure also help. Your doctor can recommend cholesterol testing and medicines if needed.
Want to Apply This Research?
- Track your total cholesterol, LDL cholesterol, and blood pressure from your regular lab or home test results, recording them each time you get them. Also log your weekly minutes of moderate exercise and daily servings of vegetables and fiber so you can see patterns over time.
- Use the app to set one small, realistic goal, such as adding one serving of vegetables to dinner or walking for 20 minutes on three days each week. Check progress each week and celebrate consistent habits rather than perfect results.
- Review your logged cholesterol results and habit data every three to six months, or as often as your doctor recommends. Share the trends with your healthcare provider so they can help you decide whether any changes are needed. Keep an eye on new research as well, but use it as a topic to discuss with your doctor, not as a reason to change medicines on your own.
This article summarizes early research conducted in mice and in laboratory cell cultures. These findings have not been tested in humans and should not be used to make decisions about diet, supplements, or medications. Anyone concerned about heart health, cholesterol, or plaque buildup should speak with a qualified healthcare professional before making changes.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.